Quinazolinone derivatives as new potential CDK4/6 inhibitors, apoptosis inducers and radiosensitizers for breast cancer

Future Med Chem. 2023 Jul;15(13):1133-1147. doi: 10.4155/fmc-2023-0126. Epub 2023 Aug 2.

Abstract

Background: Targeting CDK4/6 has advanced breast cancer treatment. Herein, new quinazolinones were synthesized with acetamide linkers as potential anti-breast cancer agents. Methods & results: In vitro cytotoxic evaluation on human breast cancer cell lines (MCF7 and MDA-MB-231) identified 1,3-benzodioxole (5d) to be of the highest potency. It showed good inhibitory activity on CDK4/6. Compound 5d arrested the cell cycle at the G1-phase, caused induction of early and late apoptosis in an Annexin V-FITC assay, led to an increase in the level of caspase-3 and upregulated Bax expression and downregulated Bcl-2 in MCF7 cells. Compound 5d showed good radiosensitizing activity when combined with a single dose of 8-Gy γ-radiation. Conclusion: This study introduces quinazolinone scaffolds as new CDK4/6 inhibitors for breast cancer.

Keywords: CDK4/6; apoptosis; breast cancer; quinazolinone; radiosensitizers.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Apoptosis
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / metabolism
  • Cell Cycle
  • Cell Line, Tumor
  • Cell Proliferation
  • Cyclin-Dependent Kinase 4 / metabolism
  • Female
  • Humans
  • Quinazolinones / pharmacology

Substances

  • Quinazolinones
  • Antineoplastic Agents
  • CDK4 protein, human
  • Cyclin-Dependent Kinase 4